Stephanie Graff, Associate Director of Global Oncology and Policy at Brown University, shared a post on X:
“Abemaciclib – per pre ESMO25 press release – improves overall survival in hormone-receptor positive early stage, high-risk BC.
A critical reminder that HR+ breast cancer is a heterogeneous disease with opportunities to increase or decrease treatment for the best outcome.”
More posts featuring Stephanie Graff.
